Consumers who purchased valsartan tablets manufactured by Hetero Labs Limited through Camber Pharmaceuticals may be eligible for compensation under a settlement valued at $11.37 million. The settlement resolves claims that the blood pressure medication was contaminated with NDMA, a probable human carcinogen, during manufacturing in India before reaching U.S. pharmacies. The contamination affected certain batches of valsartan produced between May and July 2018, though testing later revealed contaminated medications may have entered the U.S. market as early as 2014. This settlement covers purchasers of the affected recalled medications, whether the purchase was made out-of-pocket or through insurance.
Eligible claimants can receive up to $40 per 30-day supply of contaminated medication, with a maximum total of $120 per person. The claim filing window opened April 2, 2026, with a deadline of June 2, 2026, making this an active settlement requiring immediate action for those who purchased the recalled drug. The settlement received final court approval on June 30, 2026, after a hearing held at 10:00 a.m. at the U.S. District Court for the District of New Jersey. This approval means the settlement fund is now distributing payments to eligible claimants who submitted valid claim forms before the deadline.
Table of Contents
- What Was the NDMA Contamination in Hetero Valsartan?
- Settlement Timeline and Deadline Requirements
- Payment Structure and Per-Claim Calculations
- How to File a Claim and Documentation Requirements
- Limitations of Settlement Coverage and Exclusions
- Identifying Affected Medication and Batch Numbers
- Broader NDMA Contamination in Blood Pressure Drugs and Related Settlements
What Was the NDMA Contamination in Hetero Valsartan?
NDMA, or N-nitrosodimethylamine, is a chemical classified as a probable human carcinogen by both the FDA and the World health Organization. The contamination in Hetero Labs Limited’s valsartan manufacturing process was discovered during a broader investigation into ARB (angiotensin II receptor blocker) medications, which led to multiple recalls across manufacturers. The FDA formally updated its recall list on August 9, 2018, to include valsartan products produced by Hetero Labs Limited and sold under the Camber Pharmaceuticals brand in the United States.
The presence of NDMA in blood pressure medications raised significant health concerns because patients typically take these medications daily for extended periods. A consumer who took the contaminated Camber valsartan 80 mg daily for six months would have been exposed to the impurity throughout that period without knowing the medication was compromised. The FDA’s detection and recall process took time, meaning some patients may have consumed the contaminated product for months before the recall was publicly announced.
Settlement Timeline and Deadline Requirements
The claim filing deadline of June 2, 2026, also served as the objection and opt-out deadline for the settlement. This dual deadline means consumers had one date to both submit their claims for compensation and to decide whether they accepted the settlement terms. Missing this deadline typically results in forfeiture of all settlement compensation, regardless of whether the claimant qualifies based on their purchase records. Claim forms became available on April 2, 2026, giving claimants approximately two months to gather documentation and submit their claims.
Proof of purchase is generally required, such as pharmacy receipts, insurance explanation-of-benefits statements, or credit card records showing the purchase of Hetero Labs Limited valsartan manufactured between May and July 2018. Consumers without purchase documentation may still qualify in some cases by providing other evidence, such as testimonies from healthcare providers or insurance company records. The final approval hearing on June 30, 2026, at the U.S. District Court for the District of new Jersey established the court’s formal confirmation of the settlement. This does not mean claimants needed to attend the hearing; instead, the approval allowed the claims administrator to begin processing submitted forms and distributing funds.
Payment Structure and Per-Claim Calculations
Each eligible claim can receive up to $40 for every 30-day supply of the affected medication purchased. A consumer who bought six months of supply (approximately six 30-day fills) would be eligible for up to $240 based on supply alone, but the settlement caps total compensation at $120 per claimant. This cap applies regardless of how many 30-day supplies a person purchased or over what time period they took the medication.
The per-claim payment structure accounts for variations in how much medication different consumers purchased. Someone who bought a single month of valsartan on one occasion would receive up to $40, while someone who purchased multiple bottles over several months would still be capped at the $120 maximum. The settlement does not provide additional compensation based on health outcomes, documented side effects, or time spent taking the contaminated medication.
How to File a Claim and Documentation Requirements
Filing a claim requires submitting documentation to the settlement claims administrator, not to the court or directly to Hetero Labs Limited or Camber Pharmaceuticals. Pharmacy receipts, insurance documentation, or credit card statements showing the purchase date and quantity of Hetero Labs Limited valsartan are the most straightforward forms of proof. For consumers who lack original receipts, contacting their pharmacy to request purchase history records or requesting statements from their health insurance provider can provide alternative documentation.
📨 Get Free Mass Tort Guides Alerts
Free · No spam · Unsubscribe anytime
The claim form process typically requires providing personal information, proof of purchase, and details about the quantity and dates of medication purchased. Consumers should retain copies of all submitted documentation for their records, as disputes over claim amounts sometimes occur and having copies allows for faster resolution. Missing documentation deadlines or submitting incomplete forms can result in claim denial, so claimants should prioritize gathering materials well before the filing deadline.
Limitations of Settlement Coverage and Exclusions
The settlement covers only valsartan produced by Hetero Labs Limited and sold under the Camber Pharmaceuticals brand during the affected time period. A separate, larger settlement valued at $15.26 million covers combined contamination of valsartan, losartan, and irbesartan from multiple manufacturers, so consumers taking different medications or valsartan from other manufacturers may fall under different settlement programs. These separate settlements have different deadlines and payment structures, making it critical that claimants identify which settlement applies to their specific medication.
The settlement does not compensate for economic losses beyond the medication purchase price itself, such as medical expenses related to NDMA exposure, lost wages from illness, or pain and suffering. Courts determine these limitations as part of settlement approval, balancing the total fund available against the number of eligible claimants. Consumers who believe they suffered significant health effects from the contaminated medication and wish to pursue additional damages beyond the settlement amount may consult an attorney about their legal options, though pursuing individual claims after settlement approval is highly restricted.
Identifying Affected Medication and Batch Numbers
Hetero Labs Limited valsartan sold under the Camber Pharmaceuticals label in standard dosages of 40 mg, 80 mg, and 160 mg is covered by the settlement. Checking the prescription bottle label and pharmacy records for the manufacturer name “Hetero Labs Limited” or supplier designation “Camber Pharmaceuticals” confirms whether medication qualifies.
The FDA’s official recall information can be accessed for specific batch numbers affected during the May-July 2018 production window, though consumers do not need batch numbers to file claims if they have purchase documentation showing the purchase date. Consumers who no longer have their medication bottles can still qualify if purchase records show the dates and quantities purchased fell within the contamination period. Insurance company records, pharmacy systems that retain historical dispensing information, or credit card statements showing charges to pharmacy merchants can all serve as alternative proof of purchase when the physical bottle is no longer available.
Broader NDMA Contamination in Blood Pressure Drugs and Related Settlements
The NDMA contamination in valsartan was part of a larger contamination crisis affecting multiple manufacturers of ARB medications between 2018 and 2019. Losartan and irbesartan from various manufacturers were also recalled, leading to the larger $15.26 million combined settlement covering valsartan, losartan, and irbesartan products from multiple sources. Consumers taking different ARB medications should verify which specific settlement applies, as claim forms and deadlines differ between programs.
The contamination is believed to have originated from manufacturing facilities in China and India that supplied active pharmaceutical ingredients to multiple drug manufacturers. Testing later suggested contaminated ingredients may have entered the U.S. supply chain earlier than initially detected, potentially reaching patients as far back as 2014 for some products. This extended exposure window underscores why purchase documentation from any point a consumer took valsartan from Hetero Labs Limited could be relevant to their claim.
- —
You Might Also Like
- Aurobindo Blood Pressure Drug Settlement Resolves NDMA Contamination Claims
- Tyson Beef Price-Fixing Settlement Covers Consumers Who Bought Certain Beef Products
- Lakeview Loan Servicing Data Breach Settlement Covers Borrowers Affected by Cyber Incident